ABVX Abivax - ADR
15
$14.00
$0.05
(0.36%)
| Watchers | 15 |
| 52-Wk Low | $8.00 |
| 52-Wk High | $17.02 |
| Market Cap | $880.85M |
| Volume | 21,905.00 |
| 52-Wk High | $17.02 |
| 52-Wk Low | $8.00 |
Abivax publishes financial reports with the French and U.S. securities regulatory agenciesGlobe Newswire • about 1 month ago
Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France, April 5, 2024, 10:00 p.m. CEST Abivax SA (Euronext Paris & Nasdaq: ABVX) ( Abivax or the...
Share to Feed
Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and EUR...
PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ('Abivax' or the 'Company'), a clinical-stage biotechnology company focused on developing therapeutics...
Abivax appoints Ana Sharma as Vice President, Global Head of Quality PARIS, France, February 7, 2024, 8:30 a.m. CET Abivax SA (Euronext Paris and Nasdaq: ABVX) ( Abivax or the Company ), a...
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease Obefazimod Crohn's Disease (CD) IND filed with the FDA in December...
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024...
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months Induction data read-out expected Q1 2025 from the pivotal Phase 3 ABTECT program evaluating obefazimod in...
Abivax 2024 Financial Communication Calendar PARIS, France, January 4, 2024, 8:30 a.m. CET Abivax SA (Euronext Paris & Nasdaq: ABVX) ( Abivax or the Company ), a clinical-stage biotechnology...